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Time (h) Water PBS PG PEG 200 Glycerol 
PG:PGML 
(50:50) 
DMSO:Methanol 
(50:50) 
0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
24 86.1 ± 3.6 99.27 ± 4.42 99.83 ± 1.96 94.36 ± 2.34 97.64 ± 2.83 94.78 ± 5.83 93.57 ± 2.34 
48 80.7 ± 6.5 100.3 ± 4.5 103.3 ± 2.9 91.8 ± 7.8 98.4 ± 3.1 95.1 ± 4.2 99.3 ± 1.7 
72 83.7 ± 1.5 99.9 ± 2.5 98.8 ± 3.4 87.8 ± 3.6 99.5 ± 2.0 95.4 ± 1.6 98.5 ± 0.8 
96 82.5 ± 3.8 100.3 ± 2.2 99.2 ± 3.7 92.4 ± 1.7 98.3 ± 4.0 93.8 ± 1.6 98.6 ± 1.8 
120 82.6 ± 4.4 102.1 ± 1.6 104.0 ± 7.9 93.0 ± 4.2 98.3 ± 3.4 94.6 ± 3.1 102.1 ± 3.0 
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Time (h) Water PBS PG PEG 200 Glycerol 
PG:PGML 
(50:50) 
DMSO:Methanol 
(50:50) 
0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
24 98.4 ± 1.8 101.2 ± 1.3 99.4 ± 2.5 99.6 ± 0.6 97.0 ± 0.3 101.5 ± 3.7 93.1 ± 2.3 
48 99.7 ± 2.9 98.9 ± 1.5 101.1 ± 2.7 98.4 ± 1.2 101.0 ± 1.1 101.7 ± 2.6 96.3 ± 2.6 
72 99.8 ± 2.7 100.3 ± 2.1 100.8 ± 2.7 98.5± 1.9 99.8 ± 2.1 99.9 ± 2.9 98.3 ± 1.9 
96 100.0 ± 2.5 100.7 ± 0.2 100.6 ± 3.2 96.6 ± 2.5 99.5 ± 2.4 101.1 ± 4.3 97.2 ± 1.6 
120 100.3 ± 1.9 99.1 ± 2.4 101.2 ± 2.1 95.1 ± 1.5 101.4 ± 2.4 99.6 ± 2.4 102.1 ± 1.3 
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Abstract 18 
Hexamidine diisethionate (HEX D) has been used in the personal care industry and in a number of 19 
over-the-counter (OTC) drug products as an antimicrobial agent since the 1950’s. Recently, the 20 
compound has also been investigated for its beneficial effects on skin health. Surprisingly, there is 21 
only limited information describing the physicochemical properties of this compound in the 22 
literature. The objective of this work was therefore to conduct a comprehensive programme of 23 
characterisation of HEX D as well as its dihydrochloride salt (HEX H). HEX H was prepared from HEX D 24 
by a simple acid addition reaction. Both salts were characterised using Nuclear Magnetic Resonance 25 
(NMR), Differential scanning calorimetry (DSC), and Thermogravimetric analysis (TGA). A new high 26 
performance liquid chromatographic method was developed and validated for both compounds. The 27 
pH in aqueous solution as well as respective distribution coefficients between octanol and pH 7.4 28 
buffer were also determined. Finally, solubility and short term stability studies were conducted in a 29 
range of solvents. NMR analysis confirmed the preparation of HEX H from HEX D. Thermal analysis 30 
indicated the melting points of HEX D and HEX H were 225°C and 266°C respectively. HPLC analysis 31 
confirmed the purity of both salts. Log D values at pH 7.4 were -0.74 for HEX D and -0.70 for HEX H 32 
respectively. The physicochemical properties of two HEX salts have been established using a range of 33 
analytical approaches. Detailed solubility and stability data have also been collated. This information 34 
will be useful in the design of novel formulations for targeted delivery of these compounds to the 35 
skin. 36 
 37 
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1. Introduction  40 
Hexamidine (HEX) is an aromatic diamidine and a strong organic base. Although primarily 41 
used as the diisethionate salt (HEX D), it was firstly synthesised as the dihydrochloride (HEX H) and 42 
patented by Ewins et al. (1939) for May & Baker Limited (U.K.). The company was interested in the 43 
trypanocidal activity of the diamidines and the dihydrate of HEX H was subsequently demonstrated 44 
to be the most potent of the group (Ashley et al., 1942). Antiprotozoal activity was demonstrated 45 
more than 50 years later when Brasseur et al. (1994) used HEX D to treat two subjects affected by 46 
Acanthamoeba keratitis. HEX D has also shown efficacy against Pseudomonas aeruginosa, Proteus, 47 
Escherichia coli, Staphylococcus aureus and Tsukamurella paurometabolum (van Ketel, 1975; Granel 48 
et al., 1996). A more recent in-vitro study demonstrated HEX D efficacy against a series of multi-drug 49 
resistant gram-positive bacteria (Grare et al., 2010). Geratz et al. (1973) demonstrated the efficacy 50 
of HEX H dihydrate as an enzyme inhibitor with Ki values of 1.9, 4.5 and 7.4 μM, trypsin, pancreatic 51 
kallikrein and thrombin respectively. Enyedy et al. (2001) confirmed HEX inhibitory activity against 52 
thrombin (Ki value 224 nM) and matriptase (Ki = 924 nM), but did not specify if the active was used 53 
as the free base or salt. Finally, an in-vivo study  investigated the effect of two HEX salts on nitric 54 
oxide synthase (NOS). Surprisingly, while HEX D significantly decreased NOS activity, the 55 
tetrachloroplatinate (II) salt had no effect on NO generation (Morgant et al., 1998). 56 
A number of publications have focussed on the role of HEX as an anti-aging and moisturising 57 
active in cosmetics and specifically the influence of HEX on various biomarkers of corneocyte 58 
maturity and skin turnover. Kimball et al. (2012) speculated that HEX might attenuate the skin ageing 59 
process because of its inhibitory activity on serine proteases associated with skin inflammation. Both 60 
skin inflammation and abnormal lipid biosynthesis have been linked to skin ageing (McGrath et al., 61 
2012). Osborne et al. (2009) and Jarrold et al. (2010a) showed that when human skin equivalent 62 
cultures were exposed to HEX, cholesterol, fatty acid and sphingolipid biosynthesis as well as  63 
cholesterol and fatty acid uptake were downregulated while  cholesterol efflux was upregulated. 64 
Jarrold et al. (2010b) demonstrated that the application of a cosmetic moisturiser containing HEX, 65 
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niacinamide and palmitoyl-lysine-threonine significantly increased the number and size of mature 66 
corneocytes of the facial stratum corneum of twenty female subjects. Significant  thickening of the 67 
stratum corneum (SC) as well as a reduction in transepidermal water loss of the volar forearm was 68 
reported for 36 female subjects following treatment with a cream containing HEX and niacinamide 69 
(Kaczvinsky et al., 2010). However these in vivo studies did not specify if the active was used as the 70 
free base or salt. 71 
The safety of HEX and HEX D has been assessed by the Cosmetic Ingredient Review Expert 72 
Panel (2007). The panel concluded that both actives are safe when used in cosmetics at 73 
concentrations less than or equal to 0.10%. This opinion was subsequently confirmed by the 74 
European Parliament and the Council of the European Union (2009) which fixed the maximum 75 
allowed concentration of HEX and its salts in cosmetic products to 0.10%. However, several cases of 76 
allergic contact dermatitis have been reported since HEX has been in use (Gougerot et al.1950; Sidi 77 
et al., 1969;  van Ketel, 1975; Robin,1978; Dooms-Goossens et al. 1989; Brand and Ballmer-Weber, 78 
1995; Mullins, 2006;). 79 
To date, HEX D has been used as a preservative in ~40 cosmetic products  and in a number of 80 
over-the-counter formulations (Cosmetic Ingredient Review Expert Panel, 2007). Surprisingly, there 81 
is only a limited amount of information describing the physicochemical properties of HEX in the 82 
literature (British Pharmacopoeia, 2015). The use of HEX H as an alternative salt to HEX D has also 83 
not been explored. The objective, therefore, of the present work, was to undertake a comprehensive 84 
programme of characterisation of HEX D and HEX H. In the longer term this information should assist 85 
in the design of formulations which target this active more effectively to the skin.  86 
  87 
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2. Materials and Methods 88 
2.1 Materials 89 
HEX D (Laboratoires Sérobiologiques, France) was a gift from Procter & Gamble (U.S.A.), 90 
while HEX H was synthesized and purified in-house. Propylene glycol, polyethylene glycol 200, HPLC 91 
grade isopropyl alcohol, trifluoroacetic acid (HPLC grade) and absolute ethanol were supplied by 92 
Fisher Scientific (U.K.). HPLC grade solvents (acetonitrile, methanol, water), glycerol, isopropyl 93 
myristate, 1-octanol, 2-ethylhexyl salicylate, 1 M hydrochloric acid solution and dimethyl sulfoxide-94 
d6 were provided by Sigma-Aldrich (U.K.). Dimethyl sulfoxide was supplied by VWR International 95 
(U.K.). Propylene glycol monolaurate, Labrafac™ PG and Transcutol® P were received as gifts from 96 
Gattefossé (France). 1,2-pentanediol was provided by Surfachem Group (U.K.). Dimethyl isosorbide 97 
(Arlasolve®) was supplied by Croda International (U.K.). Oleic acid was provided by Fluka (U.K.). 98 
Miglyol® 812 N was supplied by Sasol (Germany). Dipropylene glycol was provided by Acros Organics 99 
(Belgium). Phosphate buffered saline was prepared using Dulbecco A tablets (Oxoid, U.K.). 100 
 101 
2.2 Methods 102 
Conversion of HEX D to HEX H 103 
Approximately 50 mL of 1 M hydrochloric acid solution were heated at 100 ± 1°C using an 104 
Ikamag® C-MAG HS 7 magnetic stirrer ceramic heating plate (IKA, Germany) equipped with an ETS-D5 105 
electronic contact thermometer (IKA, Germany). HEX D was dissolved in the solution followed by 106 
stirring of the mixture and cooling (15 min). The flask was subsequently placed on ice for 30 min to 107 
allow recrystallisation of the product. Finally, crystals were recovered by means of vacuum filtration 108 
and dried at room temperature. Hydrogen-1 and carbon-13 nuclear magnetic resonance (1H and 13C 109 
NMR) spectroscopy were used to confirm the structure of the starting material and the product of 110 
the reaction. All spectra were acquired in dimethyl sulfoxide-d6 on a Bruker Avance 400 MHz NMR 111 
spectrometer (Bruker Corporation, U.S.A.) and processed using MestReNova® 9.0.1 (Mestrelab 112 
Research, Spain). 113 
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 114 
Thermal analysis  115 
The melting points of HEX D and HEX H were examined using thermogravimetric analysis 116 
(TGA) and differential scanning calorimetry (DSC). TGA was performed using a Discovery TGA (TA 117 
Instruments, U.S.A.) system. Each active was weighed in an open aluminium pan (TA Instruments, 118 
U.S.A.) and then heated inside the Discovery TGA furnace. The starting temperature and the final 119 
temperature were set to 25°C and 400°C, respectively, while the heating ramp was 10°C/min. A 120 
nitrogen flow of 25 mL/min was supplied throughout the analysis in order to create an inert 121 
atmosphere around the sample. A DSC Q2000 (TA Instruments, U.S.A.) system was used for the DSC 122 
analysis. Each active was weighed in a hermetic aluminium pan (TA Instruments, U.S.A.) which was 123 
subsequently sealed with a hermetic aluminium lid (TA Instruments, U.S.A.) using a Tzero™ press (TA 124 
Instruments, U.S.A.). An empty hermetic aluminium pan (sealed with a hermetic aluminium lid) was 125 
used as a reference. Both the sample and reference were heated from 40°C to 290°C, with a heating 126 
ramp of10°C/min and a nitrogen flow of 50 mL/min.  127 
 128 
UV, HPLC analysis and method validation 129 
A Spectronic BioMate™ 3 UV/VIS spectrophotometer (Thermo Scientific, U.S.A.) was used to 130 
carry out an UV  scan of a solution of each active in HPLC grade water. The UV absorption spectrum 131 
was acquired between 200 and 300 nm (step = 1 nm) in order to identify the wavelength at which 132 
the absorption of light was specifically due to each active. The HPLC system consisted of a Hewlett-133 
Packard (U.S.A.) series 1100 quaternary pump, an Agilent Technologies (U.S.A.) series 1100 134 
autosampler, a Hewlett-Packard (U.S.A.) series 1100 system controller, an Agilent Technologies 135 
(U.S.A.) series 1100 degasser and an Agilent Technologies (U.S.A.) series 1100 UV detector. 136 
ChemStation® Rev.A.09.03 (Agilent Technologies, U.S.A.) software was used to analyse the data. HEX 137 
D was analysed with a Luna® 5 µm C8 150 × 4.60 mm reversed phase column (Phenomenex, U.K.) 138 
equipped with a universal HPLC guard column (Phenomenex, U.K.) packed with a SecurityGuard™ C8 139 
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cartridge (Phenomenex, U.K.). The mobile phase consisted of 75% v/v HPLC grade water (0.1% v/v 140 
HPLC grade trifluoroacetic acid) and 25% v/v HPLC grade acetonitrile. A Capcell Pak® MGIII 5 µm C18 141 
250 × 4.60 mm reversed phase column (Shiseido, Japan) was used to analyse HEX H. A universal 142 
HPLC guard column (Phenomenex, U.K.) packed with a SecurityGuard™ C18 cartridge (Phenomenex, 143 
U.K.) was attached to the column. The mobile phase consisted of 72% v/v HPLC grade water (0.1% 144 
v/v HPLC grade trifluoroacetic acid) and 28% v/v HPLC grade acetonitrile. For both HEX D and HEX H, 145 
the UV detector was set to 261 nm, the flow rate to 0.7 mL/min and the column temperature to 146 
35°C. The injection volume was set to 10 µL for HEX D and 20 µL for HEX H. Linearity, specificity, 147 
accuracy, precision, lower limit of detection (LOD) and lower limit of quantification (LOQ) of both 148 
methods were validated according to International Conference on Harmonisation of Technical 149 
Requirements for Registration of Pharmaceuticals for Human Use (2005).  150 
 151 
pH and log Do/w determination 152 
All pH measurements were taken using a SympHony® SB70P pH meter (VWR International, 153 
U.K.) at 25 ± 1°C. Four solutions of each active in deionised water were tested (0.001, 0.01, 0.1 and 1 154 
mM) with the pH of deionised water taken as the control. The method used to measure the log Do/w 155 
of HEX D and HEX H was adapted from OECD guidelines (2006). 1-octanol was mutually saturated 156 
with PBS (pH = 7.4 ± 0.5 at 25°C) by slow-stirring for 48 h at 25 ± 1°C. The system was allowed to 157 
equilibrate in a separation funnel for 24 h. Two solutions of known concentrations of HEX D or HEX H 158 
in PBS saturated with 1-octanol (pH = 7.4 ± 0.5 at 25°C) were prepared. Solutions were mixed in 159 
different proportions (1:1, 2:1 and 1:2) with 1-octanol saturated with PBS (pH = 7.4 ± 0.5 at 25°C), 160 
placed in glass test tubes sealed with Parafilm® and allowed to rotate on a rotor for 24 h at 25 ± 1°C. 161 
The two-phase systems were then left to stand and equilibrate for 48 h at the experimental 162 
temperature. At the end of the equilibration period, both phases were sampled with dilution where 163 
necessary. Amounts of HEX D and HEX H were measured by HPLC and used to calculate the log Do/w 164 
(pH = 7.4) as follows: 165 
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 166 
             
                
                       
    (Equation 1) 
 167 
Solubility and stability studies 168 
For solubility determination an excess amount of active was added to each solvent in a glass 169 
test tube containing a Teflon®-coated magnetic stir bar. The test tube was sealed with Parafilm® and 170 
placed in a SUB 28 thermostatically controlled water bath (Grant Instruments, U.K.) equipped with a 171 
Telesystem HP 15 submersible magnetic stirrer (Variomag®-USA, U.S.A.). The system was allowed to 172 
stir and equilibrate for 48 h at 32 ± 1°C to obtain a saturated solution. After the 48 h period, a 173 
sample was withdrawn from the test tube and centrifuged at 13200 rpm for 15 min at 32 ± 1°C in an 174 
Eppendorf 5415R centrifuge (Eppendorf, Germany). Finally, the supernatant was suitably diluted and 175 
the concentration of the active was determined by HPLC. Stability of HEX D and HEX H in several 176 
solvents and binary solvent systems was investigated for 120 h at 32 ± 1°C. A solution of known 177 
concentration of active was prepared and placed in a screw top glass test tube with a stir bar. The 178 
sample was sealed and allowed to stir for 120 h at 32 ± 1°C as for solubility studies and aliquots were 179 
removed at 0, 24, 48, 72, 96 and 120 h. Following sample dilution the concentration of the active 180 
was determined by HPLC.  181 
 182 
3. Results and discussion 183 
Conversion of HEX D to HEX H  184 
The hypothetical double displacement reaction between HEX D and HCl is shown in Equation 185 
2.  186 
                                                         (2) 
The 1H NMR spectrum of HEX D in dimethyl sulfoxide-d6 is shown in Figure 2a. The dimethyl 187 
sulfoxide-d6 quintuplet at 2.50 ppm was used as a reference to scale the x-axis of the spectrum.  A 188 
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water singlet at 3.30 ppm reflects the hygroscopicity of dimethyl sulfoxide-d6 which readily absorbs 189 
moisture from the atmosphere and glassware (Gottlieb et al., 1997). 190 
Figure 2a shows two triplets at 2.68 and 3.65 ppm which are assigned to the methylene 191 
hydrogens of the isethionate anion (g and h respectively), while the singlet at 4.47 ppm is assigned 192 
to the hydroxyl group (i). Interestingly, these peaks are not present in the 1H NMR spectrum of the 193 
HEX H crystals, while those for the HEX moiety of the molecule are evident (Figure 2b). In Figure 2b, 194 
the water signal is more intense than for Figure 2a and cannot be attributed solely to the moisture 195 
absorbed by the dimethyl sulfoxide-d6. This strong signal may reflect residual aqueous reaction 196 
medium or water of crystallisation which becomes trapped inside the crystals during the 197 
recrystallisation process. Further confirmation of HEX H as the product is provided by comparison of 198 
the 13C spectrum of HEX D with that of HEX H (Figures 3a and 3b ). The DMSO-d6 septuplet at 39.52 199 
ppm was used as a reference to scale the x-axis of both spectra. Two singlets at 53.69 and 57.66 ppm 200 
(Figure 3a) are assigned to the methylene carbons of the isethionate anion (9 and 10 respectively). 201 
Again, these peaks are not present in the 13C NMR spectrum of the reaction product (Figure 3b).  202 
 203 
Thermal analysis  204 
The results of the TGA and the DSC analysis of HEX D are shown in Figure 4. TGA is a well-205 
established method for the characterisation of materials and is particularly useful in determining loss 206 
of water molecules and compound degradation temperatures (Coats and Redfern, 1963). There is no 207 
weight loss of HEX D between 25°C and 290°C (Figure 4a). However, degradation occurs between 208 
300°C and 375°C and only ~ 12% of the initial weight of HEX D remains at 400°C. For DSC analysis, 209 
two endothermic events were observed; the first has an onset temperature of 176.62°C and the 210 
second is 224.86°C. It may be hypothesised that these two peaks reflect the melting of two different 211 
crystal structures of HEX D. Considering that pentamidine diisethionate, the lower homologue of 212 
HEX diisethionate, exists in at least four crystalline forms (Steele, 1990; Chongprasert et al., 1998), 213 
the possibility of multiple polymorphs of HEX D was expected. Fucke et al. (2008) identified ten 214 
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anhydrous and two dihydrate polymorphic forms of HEX D. Furthermore, the authors confirmed that 215 
HEX D does not directly melt but undergoes a phase transition (Personal communication Fucke, 216 
2015). This suggests that the first endotherm in Figure 4a is the phase transition from a low-217 
temperature form to the stable high-temperature crystal form which melts at 224.86°C. The 218 
corresponding results for DSC and TGA analyses of HEX H are shown in Figure 4b.  219 
HEX H exhibits 11.1% weight loss between 25°C and 100°C and single-stage degradation 220 
between 265°C and 350°C. Thus only ~7% of the initial weight of HEX H remains at 400°C. The initial 221 
weight loss may be attributed to the evaporation of water from the sample. This is consistent with 222 
the 1H NMR spectrum of HEX H (Figure 3) and the presence of water of crystallisation. The water 223 
content of 11.1% gives a stoichiometric ratio of three molecules of water per molecule of HEX H 224 
indicating the salt was recrystallised in its trihydrate form. DSC analysis of HEX H shows three 225 
endothermic events (Figure 4b). The first occurs between 40°C and 120°C, and represents the loss of 226 
water of crystallisation already observed in the TGA curve. The second peak has on onset 227 
temperature of 223.2°C. This value is very close to the melting point of the stable high-temperature 228 
crystal form of HEX D (Figure 4a). It might be speculated that this second endotherm was the melting 229 
of residual HEX D which was not converted to HEX H and remains as an impurity at the end of the 230 
conversion reaction. Finally, the third sharp endothermic event with an onset temperature of 231 
265.5°C is presumed to be the melting point of HEX H. 232 
 233 
UV and HPLC analysis and method validation 234 
HEX D and HEX H exhibited a suitable UV peak for analysis at 261 nm. For the HPLC analysis 235 
calibration curves (ranging from 0.5 µg/mL to 20 µg/mL) were constructed. The linearity for both 236 
methods was confirmed by the correlation coefficient (r2) which was equal to 0.99 across the 237 
experimental range. There were no interfering peaks at the retention times of the analytes which 238 
were 5. 1 min for HEX D and 8.2 min for HEX H.  Recovery of each compound within the range from 239 
90% to 110% was achieved. In addition, the %RSD for the intra-day and inter-day precision were 240 
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below 5% and 10% respectively, thus demonstrating the repeatability of the proposed methods. The 241 
LOD and LOQ for HEX D were 0.54 µg/mL and 1.64 µg/mL. The values obtained for HEX H, were 0.40 242 
µg/mL for the LOD of and 1.21 µg/mL for the LOQ. These values are also lower than values 243 
previously reported for HPLC analysis of HEX D (Taylor et al., 1983; De Bukanski and Masse, 1984). 244 
 245 
pH in aqueous solution and log Do/w at pH = 7.4 246 
Solutions of HEX D and HEX H in deionised water were as expected slightly acidic (pH ranging 247 
from 6.3 to 6.4). The log Do/w at pH = 7.4 and 25 ± 1°C and the recovery of HEX D and HEX H are 248 
reported in Table 1. Both actives showed a negative log Do/w, with HEX D having a significantly lower 249 
value than HEX H (t-test, p < 0.01). 250 
 251 
Solubility and stability  252 
The solubility at 32 ± 1°C of HEX D and HEX H in a range of different solvents is shown in 253 
Figures 5a and 5b. Data for solvents in which both actives had solubility > 1 mg/mL are pooled in 254 
Figure 5a while those in which they had solubility < 1 mg/mL are presented in Figure 5b. The only 255 
exception to this is TC which is included in both figures. HEX H, in fact, had a solubility of 2.00 mg/mL 256 
in TC while the value for HEX D was only 0.37 mg/mL.  257 
Both actives exhibited highest solubility in DMSO compared with all the other solvents 258 
studied; both actives were also soluble in PG, glycerol and methanol, sparingly soluble in 1,2-PENT 259 
and PEG 200 and only slightly soluble in PBS, ethanol, DPG and TC (HEX H only). In addition, HEX D 260 
was soluble in water, while HEX H was only sparingly soluble in water.  The solubility of HEX D  and 261 
HEX H in water was fifteen and ten times, respectively, higher than that in PBS (pH = 7.4). 262 
Considering that the pH of water was 6.36 and that the pKa of the amidino group of HEX is 11, the 263 
increase in pH resulted in a lower ionisation and, as a result, in a lower solubility of the actives in 264 
PBS. This effect of pH on solubility is commonly accepted and Avdeef (2007) has recently reviewed 265 
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how it affects sparingly soluble ionisable drugs. The presence of other ions and components of the 266 
buffer is also expected to influence the solubility values obtained. For example, it is possible that 267 
phosphate anions may interact with hexamidine cations, precipitate them and reduce hexamidine 268 
concentration in solution. As no information is available in the literature on phosphate salts of HEX 269 
this is an area which deserves further investigation.  270 
With the exception of TC and IPA, both HEX D and HEX H were practically insoluble in all 271 
other solvents studied. HEX H in particular, was so poorly soluble in 2-EHSAL, IPM and LABR that its 272 
solubility was below the LOQ (1.21 µg/mL) for HPLC analysis. The percentage of HEX D recovered 273 
after 24, 48, 72, 96 and 120 h at 32 ± 1°C in a series of solvents and selected binary solvent systems 274 
is shown in Table 2. The results summarised in Table 2 indicate that HEX D exhibits some instability 275 
in water. At 24 h recovery was 86.1 ± 3.6 % but there was no further degradation.  Conversely, HEX D 276 
did not undergo degradation in the other solvents and binary solvent systems tested. Less than 8 % 277 
loss was observed after 120 h in PBS, PG, PEG 200, glycerol, PG:PGML (50:50) and DMSO:Methanol 278 
(50:50).The results of the stability studies of HEX H in the same solvents and binary solvent systems 279 
seen for HEX D are presented in Table 3. HEX H did not show any stability issues (Table 3) and less 280 
than 5 % loss was observed after 120 h in water, PBS, PG, PEG 200, glycerol, PG:PGML (50:50) and 281 
DMSO:Methanol (50:50). 282 
 283 
4. Conclusions 284 
The selection of an active ingredient and the characterisation of its physicochemical 285 
properties is arguably the most important stage in the preformulation design of a topical. All 286 
available information about HEX and its salts was identified and reviewed. Although HEX D is the 287 
active that is currently used in personal care and pharmaceutical formulations, its dihydrochoride 288 
salt, HEX H also appears to be a suitable candidate molecule for delivery to the skin. We have 289 
confirmed that HEX H has a lower MW than HEX D but a higher melting point. Thermal analysis also 290 
confirmed that HEX D exists in different crystal forms and revealed that HEX H had recrystallised as a 291 
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trihydrate during the conversion process. The measurement of the pH of the solutions of HEX D and 292 
HEX H in deionised water demonstrated that both salts are very weakly acidic. New HPLC analytical 293 
methods for the quantification of HEX D and HEX H were developed and validated. The solubility of 294 
HEX D and HEX H was studied in 19 solvents and both actives were found to be more soluble in those 295 
solvents having polar properties. The stability of HEX D and HEX H in solution and in a limited 296 
number of combinations of selected excipients was also evaluated. Overall, the findings are 297 
expected to be useful in the rational design of new formulations for both actives.  298 
 299 
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